LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Home・Aandelen Lijst・Waters Corp

Waters Corp

Gesloten

SectorGezondheidszorg

300.36 -2.89

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

298.03

Max

309.62

Belangrijke statistieken
By Trading Economics
Inkomsten	26M 147M
Verkoop	110M 771M
K/W Sectorgemiddelde	27.238 35.733
EPS	2.95
Winstmarge	19.072
Werknemers	7,600
EBITDA	92M 244M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+15.81% upside

Dividenden
By Dow Jones
Volgende Winsten	31 okt 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	969M 18B
Vorige openingsprijs	303.25
Vorige sluitingsprijs	300.36

Nieuwssentiment

By Acuity

29%

71%

97 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

345.22 / 351.01 Steun & Weerstand

Waters Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 jul 2025, 14:26 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

14 jul 2025, 11:08 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

15 jul 2025, 18:32 UTC

Acquisities, Fusies, Overnames

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 jul 2025, 18:31 UTC

Acquisities, Fusies, Overnames

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

14 jul 2025, 16:53 UTC

Populaire aandelen

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14 jul 2025, 16:12 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

14 jul 2025, 15:06 UTC

Acquisities, Fusies, Overnames

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

14 jul 2025, 14:11 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

14 jul 2025, 10:53 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

14 jul 2025, 10:22 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

14 jul 2025, 10:22 UTC

Acquisities, Fusies, Overnames

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

14 jul 2025, 10:22 UTC

Acquisities, Fusies, Overnames

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

14 jul 2025, 10:21 UTC

Acquisities, Fusies, Overnames

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

14 jul 2025, 10:20 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

14 jul 2025, 10:19 UTC

Acquisities, Fusies, Overnames

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

14 jul 2025, 10:19 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

14 jul 2025, 10:18 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

14 jul 2025, 10:18 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

14 jul 2025, 10:17 UTC

Acquisities, Fusies, Overnames

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

14 jul 2025, 10:16 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

14 jul 2025, 10:16 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

14 jul 2025, 10:15 UTC

Acquisities, Fusies, Overnames

Waters to Combine With Becton Dickinson's Biosciences & Diagnostic Solutions Business >WAT BDX

14 jul 2025, 10:15 UTC

Acquisities, Fusies, Overnames

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine

Peer Vergelijking

Prijswijziging

Waters Corp Prognose

Koersdoel

By TipRanks

15.81% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 358.29 USD 15.81%

Hoogste 465 USD

Laagste 300 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Waters Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

14 ratings

Buy

Hold

Sell

Gebaseerd op 14 analisten die aandelenratings hebben gegeven aan Waters Corp - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

345.22 / 351.01Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

97 / 371 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Waters Corp

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.